AstraZeneca begins COVID-19 prevention trials of antibody cocktail |
Clinical News
eMediNexus Coverage from: 
AstraZeneca begins COVID-19 prevention trials of antibody cocktail

2 Read Comments                

AstraZeneca has initiated the late-stage clinical trials of an experimental long-acting monoclonal antibody combination drug, which the company hopes could be a prophylactic to prevent COVID-19 infection in at-risk individuals for up to 12 months.

The Phase III international clinical trial is going to recruit 5,000 individuals across Europe and the United States to determine the safety and effectiveness of the antibody cocktail, known as AZD7442. The prophylactic treatment introduces antibodies, rather than inciting the body’s immune system to make them. The treatment may prove useful in individuals whose immune systems are weaker or compromised, and those who donot respond to vaccination. The trials of the monoclonal antibody combination started on Saturday in Britain, and will recruit 1,000 participants at nine sites… (Reuters, November 21, 2020)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now